HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes: Difference between revisions

|''ETV6::NTRK3'' is reported in multiple cancers but rare < 5% in acute lymphoblastic leukemia. <ref>{{Cite journal|last=Knezevich|first=S. R.|last2=Garnett|first2=M. J.|last3=Pysher|first3=T. J.|last4=Beckwith|first4=J. B.|last5=Grundy|first5=P. E.|last6=Sorensen|first6=P. H.|date=1998-11-15|title=ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma|url=https://pubmed.ncbi.nlm.nih.gov/9823307|journal=Cancer Research|volume=58|issue=22|pages=5046–5048|issn=0008-5472|pmid=9823307}}</ref><ref>{{Cite journal|last=Tognon|first=Cristina|last2=Knezevich|first2=Stevan R.|last3=Huntsman|first3=David|last4=Roskelley|first4=Calvin D.|last5=Melnyk|first5=Natalya|last6=Mathers|first6=Joan A.|last7=Becker|first7=Laurence|last8=Carneiro|first8=Fatima|last9=MacPherson|first9=Nicol|date=2002-11|title=Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma|url=https://pubmed.ncbi.nlm.nih.gov/12450792|journal=Cancer Cell|volume=2|issue=5|pages=367–376|doi=10.1016/s1535-6108(02)00180-0|issn=1535-6108|pmid=12450792}}</ref><ref>{{Cite journal|last=Alessandri|first=A. J.|last2=Knezevich|first2=S. R.|last3=Mathers|first3=J. A.|last4=Schultz|first4=K. R.|last5=Sorensen|first5=P. H.|date=2001-10|title=Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias|url=https://pubmed.ncbi.nlm.nih.gov/11568911|journal=Medical and Pediatric Oncology|volume=37|issue=4|pages=415–416|doi=10.1002/mpo.1222|issn=0098-1532|pmid=11568911}}</ref>

|The ''ETV6::NTRK3'' responded to the ALK inhibitory crizotinib.<ref>{{Cite journal|last=Roberts|first=Kathryn G.|last2=Li|first2=Yongjin|last3=Payne-Turner|first3=Debbie|last4=Harvey|first4=Richard C.|last5=Yang|first5=Yung-Li|last6=Pei|first6=Deqing|last7=McCastlain|first7=Kelly|last8=Ding|first8=Li|last9=Lu|first9=Charles|date=2014-09-11|title=Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/25207766|journal=The New England Journal of Medicine|volume=371|issue=11|pages=1005–1015|doi=10.1056/NEJMoa1403088|issn=1533-4406|pmc=4191900|pmid=25207766}}</ref> Prognosis is not well defined due to the small number of cases.